sign up for news or events
One stop shop services.
Doppel has its own dedicated R&D organization staffed by highly quailed and specialized scientists and equipped with a broad range of advanced technologies to run R&D activities
Trilantic Capital Partners Europe (“Trilantic Europe”), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici (“Doppel” or the “Company”), after obtaining anti-trust approvals. Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging.+ read more